The incident, identified in July 2026, involved unauthorized access to external cloud storage providers used by the pharmaceutical firm. Amgen officially classified the breach as material in its Form 8-K filing, yet the company has stopped short of revealing how many people had their data compromised. This silence has raised concerns regarding potential violations of state and federal notification requirements.
Legal experts are now examining whether the exposure included patient protected health information and proprietary company data. Those affiliated with the firm may face heightened risks of identity theft, prompting the San Francisco-based law firm to evaluate potential class action litigation. The investigation aims to secure both financial damages for those impacted and a court-mandated overhaul of Amgen’s current cybersecurity protocols.
Comments (0)
No comments yet. Be the first!